Kyverna Therapeutics (NASDAQ:KYTX) Chief Executive Warner Biddle said the company is advancing toward a potential first launch of its lead CAR-T therapy, miv-cel, in autoimmune disease, with its initial focus on Stiff Person Syndrome, during a fireside chat hosted by H.C. Wainwright senior biotech analyst Mitchell Kapoor. Biddle said Kyverna has begun a rolling biologics [...]